Christine Ring, Nurix Therapeutics' Chief Legal Officer, sold 28,935 shares for $580,505 on June 25, 2026, through a Rule 10b5-1 plan. The transaction occurred as the stock approached its 52-week high of $23.09, following a 93% annual return. Concurrently, Ring acquired 28,935 shares via stock option exercises. Nurix recently reported updated clinical data for bexobrutideg and announced a $700 million upfront partnership with Roche for co-development and U.S. commercialization. Analysts from Stifel, H.C. Wainwright, UBS, and Jefferies reaffirmed Buy ratings, with Jefferies raising its price target to $45.
Summarize with
Key Points
- Nurix Therapeutics executive Christine Ring sold 28,935 shares for $580,505 under a Rule 10b5-1 plan, while simultaneously acquiring 28,935 shares via stock option exercises totaling $232,847.
- The company announced a major partnership with Roche for bexobrutideg, featuring a $700 million upfront payment and up to $2.3 billion in milestones, with development costs split 40/60.
- Analysts from Stifel, H.C. Wainwright, UBS, and Jefferies reaffirmed Buy ratings, with Jefferies raising its price target to $45, citing the partnership's potential and clinical data.
Christine Ring, serving as the Chief Legal Officer for Nurix Therapeutics, Inc. (NRIX), executed a sale of 28,935 shares of the company's common stock on June 25, 2026. The transaction generated a total value of $580,505. These sales were conducted in accordance with a Rule 10b5-1 trading plan that Ms. Ring had established in advance. The timing of this divestment coincides with the stock trading near its 52-week peak of $23.09. Over the preceding twelve months, the shares have delivered a 93% return. Market analysis indicates that the current valuation appears elevated relative to its estimated fair value, with the stock exhibiting significant price volatility.
The shares were disposed of at a weighted average price of $20.0624 per share. Individual transaction prices for these shares fluctuated between $20.00 and $20.40. On the identical date, Ms. Ring simultaneously acquired a matching quantity of 28,935 shares through the exercise of employee stock options. This acquisition comprised 13,333 shares exercised at a price of $7.26 per share and 15,602 shares exercised at $8.72 per share. The total cost incurred for these option exercises totaled $232,847. The vesting schedule for the options on 13,333 shares was completed on January 18, 2024. The options covering the remaining 15,602 shares commenced monthly vesting on March 13, 2024, with full vesting scheduled for February 13, 2027.
Following these combined transactions, Ms. Ring's direct ownership of Nurix Therapeutics common stock stands at 13,579 shares. In a parallel development, Nurix Therapeutics has disclosed updated clinical trial results for bexobrutideg, its investigational oral BTK degrader being evaluated for chronic lymphocytic leukemia. This data was presented at the European Hematology Association Congress. Furthermore, the company has formalized a substantial collaboration agreement with Roche. This partnership encompasses the co-development and U.S. co-commercialization of bexobrutideg. The financial terms include a $700 million upfront payment and potential milestone payments reaching up to $2.3 billion. Under the agreement, the companies will share profits and losses equally within the U.S. market. Globally, development costs will be allocated with Nurix responsible for 40% and Roche for 60%.
Analysts from Stifel, H.C. Wainwright, UBS, and Jefferies have responded positively to these developments. All four firms have reiterated Buy ratings on Nurix stock. Jefferies specifically increased its price target from $41 to $45, highlighting the potential of the partnership. Stifel expressed confidence in the clinical trial data for bexobrutideg, supporting its superiority in upcoming trials. These collaborative and clinical advancements position Nurix favorably among investment firms.
The stock price data reflects recent trading activity. The closed price was recorded at 22.46, representing an increase of 3.16 or 16.37%. After-hours trading showed a price of 22.55, an increase of 0.09 or 0.40%. The trading period analyzed spans from 14:00 to 19:00. The data visualization tool used is Highcharts 11.4.8.
Risks
- The stock currently appears overvalued relative to its fair value according to market analysis, indicating potential valuation risks for investors.
- High volatility in the stock price suggests uncertainty in market perception and potential price fluctuations following the partnership announcement.
- The clinical trial data for bexobrutideg is still investigational, and future trial results may not meet expectations, impacting the partnership's value.